1. New Paradigms in M0 CRPC

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Case Study Presentation

5. Case Study Presentation (cont)

6. Managing M0 CRPC

7. Changes to Guidelines for Managing M0 CRPC

8. PROSPER Trial Enzalutamide in M0 CRPC

9. PROSPER MFS Favoring Enzalutamide

10. PROSPER PSA Progression

11. PROSPER First Use of Subsequent Antineoplastic Therapy

12. PROSPER Adverse Events

13. PROSPER Patient-Reported Outcomes

14. SPARTAN Trial Apalutamide in M0 CRPC

15. SPARTAN MFS

16. SPARTAN Prespecified Secondary and Exploratory Efficacy Endpoints

17. SPARTAN Updated Analysis of PFS2 with First Subsequent Therapy and Safety

18. SPARTAN AEs With Apalutamide vs Placebo

19. SPARTAN Quality of Life Mean Scores

20. Next-Generation Androgen Receptor Inhibitors

21. ARAMIS Trial Darolutamide in M0 CRPC

22. ARAMIS MFS

23. ARAMIS OS

24. ARAMIS Time to Pain Progression (BPI-SF)

25. ARAMIS Select Treatment-Related AEs of Interest

26. How Do We Choose Between Agents?

27. Bone Health Preservation

28. New Imaging Modalities

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)